<DOC>
	<DOCNO>NCT02721056</DOCNO>
	<brief_summary>The purpose Phase I / II study evaluate safety preliminary efficacy NBTXR3 nanoparticles give intralesional ( IL ) intraarterial ( IA ) injection activate Stereotactic Body Radiation Therapy treatment liver cancer .</brief_summary>
	<brief_title>NBTXR3 Crystalline Nanoparticles Stereotactic Body Radiation Therapy Treatment Liver Cancers</brief_title>
	<detailed_description>This prospective , open-label , non-comparative non-randomized study , conduct 2 phase : - dose-escalation phase , determine recommend dose NBTXR3 evaluate safety/tolerability preliminary clinical activity ; - dose-expansion phase , cohort expansion recommend dose NBTXR3 . Patients receive single administration NBTXR3 day injection , super selective transcatheter arterial intrahepatic lesion injection activate Stereotactic Body Radiation Therapy start 24 hour post injection . The total radiotherapy dose maximum 45 Gy , deliver three fraction 15 Gy max , 5 7 day ( 45 Gy , 3x15 Gy , 5 7 day ) . visit End Treatment ( EOT ) take place 12 13 week administration last radiotherapy fraction include evaluation global clinical , radiological laboratory parameter .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Age ≥ 18 Written Informed Consent obtain , sign dated Eastern Cooperative Oncology Group performance status 0 1 Life expectancy &gt; 6 month Liver metastases primary cancer 1 ) histologic confirmation metastasis , 2 ) histologic confirmation primary cancer multiple new enhance lesion liver consistent metastasis , 3 ) histologic confirmation primary cancer grow enhance lesion liver consistent metastasis Unresectable tumor/s , base opinion experience surgeon specialize hepatic resection , patient must medically inoperable Patients extrahepatic metastasis control supportive care concomitant hormonotherapy eligible . Previous liver resection local treatment ( radiofrequency ablative therapy , chemoembolization , microwave treatment… ) permit Patients must recover effect previous therapy ( residual AE grade 0 1 ) At least one tumor lesion accurately measure least one dimension accord RECIST 1.1 Normal permeability hepatic artery evaluate injected CTscan ( arterial phase ) 700 cc liver volume without tumor involvement radiation therapy dose &lt; 15 Gy Female patient must negative serum/urinary pregnancy test The following laboratory parameter : Platelet count ≥ 50 x 10^9/L Hemoglobin ≥ 8.5 g/dL Absolute neutrophil count ≥ 1.5 x 10^9/L , Prothrombin Ratio &gt; 50 % Prothrombin time International Normalized Ratio ( INR ) &lt; 1.5 correctable vitamin K Patients receive anticoagulation antiaggregant therapy must stop temporarily treatment . Total bilirubin &lt; 30 μmol/l Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) = &lt; 5 x upper limit normal Albumin &gt; 2.5 g/dL Very low undetectable Hepatitis B Virus DNA Hepatitis C Virus RNA Serum Creatinine ≤ 1.5 time upper limit normal value Glomerular Filtration Rate &gt; 44 mL/min/1.73m2 Pa O2 &gt; 85 mm Hg Patients ongoing chronic active viral B C hepatitis must receive antiviral treatment negativation viremia low viremia onset radiation therapy Biliary tract dilatation , biliodigestive anastomosis , bile duct drainage Uncontrolled extrahepatic metastatic disease symptomatic treatment well tolerate hormonotherapy ( AE 0/1 ) Previous cancer cure less 2 year Previous anticancer treatment ( chemotherapy or/and biologicals ) wash &lt; 4 week Previous treatment intraarterial injection Y90 load microspheres Previous intraarterial chemotherapy Prior radiation therapy right upper abdomen , preclude reirradiation liver . That , previous radiation therapy mean dose liver 15 Gy conventional fractionation deliver , previous dos critical normal structure would make reirradiation unsafe Impossibility follow dosimetry constraint ( mean total liver dose &gt; 15Gy ) Presence arterioveinous intra tumoral shunt Encephalopathy relate liver failure Clinical ascitis Previous concurrent cancer distinct primary site histology Hepatocellular Carcinoma , except cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor ( Ta , Tis &amp; T1 ) Presence hepato pulmonary syndrome Auto immune hemolytic anemia Auto immune disorder , excepted auto immune thyroiditis Uncontrolled hypertension congestive heart failure Active coronary artery disease ( myocardial infarction 6 month prior study entry permit ) Previous gastrointestinal bleed within past 2 month Known syndrome AIDSrelated illness serious non control acute chronic illness Active , clinically severe bacterial fungal infection ( &gt; grade 2 CTCAE , version 4.0 ) Complete initial work earlier 4 week prior patient registration Patient whose general health condition allow treatment feasibility Patients unable and/or unwilling comply schedule visit , treatment plan , laboratory test , study procedure Patients participate another clinical investigation time signature inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>